Omnicell, Inc.

NasdaqGS:OMCL Voorraadrapport

Marktkapitalisatie: US$1.9b

Omnicell Inkomsten in het verleden

Verleden criteriumcontroles 1/6

De winst van Omnicell is gedaald met een gemiddeld jaarlijks percentage van -38.1%, terwijl de winst van de Medical Equipment -industrie jaarlijks groeide met 10.4%. De inkomsten zijn groeide met een gemiddeld percentage van 1.2% per jaar. Het rendement op het eigen vermogen Omnicell bedraagt 1.6% en de nettomarge bedraagt 1.7%.

Belangrijke informatie

-38.09%

Groei van de winst

-39.43%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie8.90%
Inkomstengroei1.22%
Rendement op eigen vermogen1.63%
Nettomarge1.67%
Laatste winstupdate31 Mar 2026

Recente prestatie-updates uit het verleden

Recent updates

OMCL: New Product Cycle Will Reset Expectations And Support Higher Future Earnings Multiple

Analysts have reset their view on Omnicell, with the consolidated fair value estimate moving from $49.00 to $55.00. This reflects updated assumptions on discount rate, growth, margins and future P/E, alongside recent price target hikes and rating changes across the Street.

OMCL: New Product Cycle Will Drive Next Cabinet Super Cycle

Narrative Update on Omnicell Analysts now see a slightly lower blended price target for Omnicell, with recent moves spanning a $14 cut at one firm and a $10 increase at another. They are weighing a new product cycle against differing views on execution and risk.

OMCL: Cabinet Replacement Cycle Will Drive Future Super Cycle Repricing

Narrative Update on Omnicell The updated analyst price target for Omnicell has shifted by $14 as analysts balance recent upgrades tied to a new product cycle and cabinet replacement opportunity against a lower target from one firm, while keeping the model's fair value estimate steady at $49. Analyst Commentary Recent research on Omnicell presents a mixed picture, with some firms highlighting upside linked to a new product cycle and cabinet replacement opportunity, while more cautious voices are resetting expectations and price targets.

OMCL: Cabinet Replacement Cycle Will Drive Future Risk Reward Repricing

Analysts have trimmed the Omnicell fair value estimate from $50.00 to $49.00, reflecting slightly softer assumptions for revenue growth and profit margins, even as they factor in a higher future P/E multiple supported by recent upgrades tied to the new product cycle and cabinet refresh story. Analyst Commentary Recent Street research on Omnicell has been mixed, with some firms trimming price targets while others turn more constructive on the new product cycle and cabinet refresh opportunity.

OMCL: Cabinet Replacement Cycle Will Drive Future Medication Management Upside

Analysts have adjusted their Omnicell price target by $14, reflecting mixed research that includes both target cuts and upgrades related to expectations around the new product cycle and potential cabinet replacement demand. Analyst Commentary Bullish Takeaways Bullish analysts see the new Titan XT cabinets as a key product that could support higher long term growth expectations if hospitals move ahead with planned cabinet replacements.

OMCL: Cabinet Refresh Cycle Will Support Future Medication Management Upside

Analysts have nudged their fair value estimate for Omnicell higher from $51.50 to about $57.43, citing updated views on its product cycle and cabinet refresh opportunity as reflected in recent research. Analyst Commentary Recent research coverage on Omnicell reflects a mix of optimism around the new product cycle and cabinet refresh, alongside some restraint on how quickly that opportunity may translate into value.

Why Investors Shouldn't Be Surprised By Omnicell, Inc.'s (NASDAQ:OMCL) 26% Share Price Plunge

Feb 12
Why Investors Shouldn't Be Surprised By Omnicell, Inc.'s (NASDAQ:OMCL) 26% Share Price Plunge

OMCL: Cabinet Replacement Cycle Could Drive Upside In Concentrated Market

Analysts have raised their fair value estimate for Omnicell to US$63 from US$55, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. This change is supported by recent positive research on the potential impact of the Titan XT cabinet cycle and competitive wins.

OMCL: Cabinet Replacement Cycle Will Shape Future Risk Reward Balance

Narrative Update on Omnicell The analyst price target for Omnicell has moved from $43 to $50 as analysts point to potential cabinet replacement demand and the Titan XT launch as key drivers for expected improvements in sales, earnings, and valuation assumptions. Analyst Commentary Recent research highlights a more constructive tone around Omnicell, with some analysts pointing to a potential cabinet replacement cycle and the Titan XT launch as key themes in their work.

OMCL: Future Medication Management Platform Rollout Will Support Balanced Risk Reward Profile

Analysts have lifted their price target on Omnicell from US$34 to US$43, pointing to updated assumptions for slightly lower discount rates, firmer revenue growth, improved profit margins, and a more moderate future P/E outlook. What's in the News Omnicell launched Omnicell Titan XT, an enterprise version of its automated dispensing systems designed to unify automation with its cloud-based OmniSphere medication management platform, aiming to create a connected, enterprise-wide medication management ecosystem across care areas.

OMCL: New Medication Management Platform Will Support Future Upside Potential

Analysts have raised their price target on Omnicell from approximately 47.33 dollars to 51.50 dollars. This change reflects slightly lower perceived risk, modestly stronger long term profit margins, and a higher expected future earnings multiple.

OMCL: Share Repurchases Will Support Future Upside Potential

Analysts have modestly raised their price target on Omnicell to approximately $47.33 per share, reflecting slightly lower perceived risk and stable, long-term growth and profitability expectations. What's in the News Updated fourth quarter 2025 revenue guidance to a range of $306 million to $316 million, signaling stable near term demand (company guidance).

OMCL: Share Repurchases And Executive Shifts Will Drive Future Upside

Analysts have revised their price target for Omnicell, lowering it modestly to $47.33 per share. This change reflects slight adjustments in key financial assumptions and uncertainty regarding future growth rates.

Improved Revenues Required Before Omnicell, Inc. (NASDAQ:OMCL) Stock's 25% Jump Looks Justified

Nov 13
Improved Revenues Required Before Omnicell, Inc. (NASDAQ:OMCL) Stock's 25% Jump Looks Justified

OMCL: Share Repurchases And Leadership Transition Will Strengthen Market Position

Omnicell's analyst price target has been raised from $44 to approximately $47.33 per share. Analysts cite improved outlooks for revenue growth, profit margins, and lower discount rates as reasons supporting the upward revision.

Omnicell Q2 Earnings: Market Ignoring The Segments

Jul 31

Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital

Jul 16
Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital

Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Jun 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate
User avatar

Near-shoring And Digitization Will Drive Stability Despite Tariff Challenges

Supply chain improvements and near-shoring are expected to offset cost pressures, while a shift to recurring SaaS and services enhances earnings stability and valuation potential.

It Looks Like Omnicell, Inc.'s (NASDAQ:OMCL) CEO May Expect Their Salary To Be Put Under The Microscope

May 14
It Looks Like Omnicell, Inc.'s (NASDAQ:OMCL) CEO May Expect Their Salary To Be Put Under The Microscope

US$38.50: That's What Analysts Think Omnicell, Inc. (NASDAQ:OMCL) Is Worth After Its Latest Results

May 09
US$38.50: That's What Analysts Think Omnicell, Inc. (NASDAQ:OMCL) Is Worth After Its Latest Results

Omnicell (NASDAQ:OMCL) Seems To Use Debt Rather Sparingly

Apr 07
Omnicell (NASDAQ:OMCL) Seems To Use Debt Rather Sparingly

Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?

Mar 20
Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?

Why Omnicell's (NASDAQ:OMCL) Earnings Are Better Than They Seem

Feb 14
Why Omnicell's (NASDAQ:OMCL) Earnings Are Better Than They Seem

Omnicell Q4 Earnings: Ignore The Short-Term Noise

Feb 12

Results: Omnicell, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 09
Results: Omnicell, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate

Jan 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate

Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues

Nov 27
Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues

Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next

Nov 02
Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next

Omnicell Q3 Earnings: Look At The Growth Segment

Nov 01

Is It Time To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Oct 31
Is It Time To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

Oct 07
Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

Opbrengsten en kosten

Hoe Omnicell geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:OMCL Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
31 Mar 261,2252040989
31 Dec 251,185240988
30 Sep 251,1782040592
30 Jun 251,1502339889
31 Mar 251,1362139089
31 Dec 241,1121338090
30 Sep 241,064-1837388
30 Jun 241,080-2138391
31 Mar 241,103-2139693
31 Dec 231,147-2042693
30 Sep 231,186-3445497
30 Jun 231,235-2346397
31 Mar 231,268-18475101
31 Dec 221,2966466101
30 Sep 221,3094845396
30 Jun 221,2586143891
31 Mar 221,1997241283
31 Dec 211,1327838176
30 Sep 211,0708035469
30 Jun 219876032765
31 Mar 219143530665
31 Dec 208923229766
30 Sep 208913829870
30 Jun 209064929871
31 Mar 209246929870
31 Dec 198976129069
30 Sep 198605427467
30 Jun 198364826966
31 Mar 198073826664
31 Dec 187873825965
30 Sep 187725425864
30 Jun 187544824964
31 Mar 187474424567
31 Dec 177133124166
30 Sep 17688-123365
30 Jun 17678-623864
31 Mar 17670-924360
31 Dec 166961023058
30 Sep 16651823152
30 Jun 165991421046
31 Mar 165392418441
31 Dec 154853116535
30 Sep 154763216634
30 Jun 154633216432

Kwaliteitswinsten: OMCL heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (1.7%) OMCL } zijn lager dan vorig jaar (1.9%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van OMCL is de afgelopen 5 jaar met 38.1% per jaar gedaald.

Versnelling van de groei: De winstgroei OMCL is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: OMCL had het afgelopen jaar een negatieve winstgroei ( -3.5% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Medical Equipment ( 13.2% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 1.6% ) van OMCL wordt als laag beschouwd.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/03 06:19
Aandelenkoers aan het einde van de dag2026/05/01 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Omnicell, Inc. wordt gevolgd door 20 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Raymond MyersBenchmark Company
William SutherlandBenchmark Company
Zhilin LongBerenberg